Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $8.3 million.

  • UroGen Pharma's Cash from Financing Activities fell 7911.43% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year decrease of 9554.29%. This contributed to the annual value of $194.6 million for FY2024, which is 6643.92% up from last year.
  • UroGen Pharma's Cash from Financing Activities amounted to $8.3 million in Q3 2025, which was down 7911.43% from $296000.0 recorded in Q2 2025.
  • UroGen Pharma's 5-year Cash from Financing Activities high stood at $116.1 million for Q3 2023, and its period low was -$168000.0 during Q3 2021.
  • Over the past 5 years, UroGen Pharma's median Cash from Financing Activities value was $671000.0 (recorded in 2023), while the average stood at $25.8 million.
  • In the last 5 years, UroGen Pharma's Cash from Financing Activities tumbled by 37540.98% in 2021 and then skyrocketed by 176845000.0% in 2022.
  • Over the past 5 years, UroGen Pharma's Cash from Financing Activities (Quarter) stood at -$32000.0 in 2021, then surged by 79375.0% to $25.4 million in 2022, then plummeted by 99.84% to $40000.0 in 2023, then soared by 77.5% to $71000.0 in 2024, then skyrocketed by 11550.7% to $8.3 million in 2025.
  • Its Cash from Financing Activities was $8.3 million in Q3 2025, compared to $296000.0 in Q2 2025 and $34000.0 in Q1 2025.